By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





Company News
Gilead Sciences, Inc. (GILD) Looks To Erase Bristol-Myers Squibb Company (BMY)'s Early Hep C Lead 9/30/2014 7:05:34 AM
Bristol-Myers Squibb Company (BMY) Positive Phase 3 Data For Opdivo (Nivolumab) In Advanced Melanoma Patients Previously Treated With Yervoy (Ipilimumab) Presented At The ESMO 2014 Congress; First Phase 3 Results Presented For A PD-1 Immune Checkpoint Inhibitor 9/29/2014 11:55:22 AM
Bristol-Myers Squibb Company (BMY) Release: European Medicines Agency Validates The Marketing Authorization Application For Nivolumab In Non-Small Cell Lung Cancer 9/29/2014 11:41:00 AM
Bristol-Myers Squibb Company (BMY) And Pfizer (PFE) Announce Charitable Donations Of More Than $1 Million To Support Cardiovascular Education For Patients And Caregivers 9/22/2014 10:39:51 AM
Bristol-Myers Squibb Company (BMY) Takes Immunotherapy Rivalry With Merck & Co. (MRK) To The Courts 9/8/2014 5:49:28 AM
Bristol-Myers Squibb Company (BMY) Release: Secondary Analysis Of AMPLIFY-EXT Examining Predictors Of Hospitalization Presented At ESC Congress: Eliquis (Apixaban) Significantly Reduced The Risk Of All-Cause Hospitalization Versus Placebo In Patients With Venous Thromboembolism (VTE) 9/2/2014 1:24:03 PM
Bristol-Myers Squibb Company (BMY) To Take Part In Morgan Stanley (MST) Global Health Care Conference 9/2/2014 10:56:14 AM
Bristol-Myers Squibb Company (BMY) Gives Back Rights To Alder Biopharmaceuticals Inc.'s Promising Arthritis Drug Clazakizumab 9/2/2014 8:12:26 AM
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) To Present New Data On Eliquis® (Apixaban) At The European Society of Cardiology Congress 2014 8/20/2014 8:41:27 AM
Bristol-Myers Squibb Company (BMY) And Celgene (CELG) Enter Clinical Collaboration Agreement To Evaluate Immunotherapy And Chemotherapy Combination Regimen 8/20/2014 8:25:44 AM
12345678910...
//-->